Sun Pharma to acquire U.S. based Organon in $11.75 billion all-cash deal
Mumbai: Sun Pharmaceutical Industries Ltd has entered into a definitive agreement to acquire all outstanding shares of U.S. healthcare firm Organon for $14.00 per share, in an all-cash transaction that values the company at $11.75 billion.
The deal, announced April 27, 2026, marks one of the largest overseas acquisitions by an Indian drugmaker. Organon is a global healthcare company that was formed through a spinoff from Merck, known as MSD outside the United States and Canada, in 2021.
The acquisition gives Sun Pharma a significant footprint in women’s health, biosimilars, and established brands, expanding its presence in the U.S. and other regulated markets. Organon’s portfolio includes treatments in reproductive health, contraception, and several legacy products spun off from Merck.
Sun Pharma said the transaction will be funded through cash on hand and is expected to strengthen its global specialty and generics business. The enterprise valuation of $11.75 billion reflects Organon’s scale and commercial infrastructure built since the 2021 spinoff.
The move comes as Indian pharmaceutical majors look to diversify beyond generics and deepen their presence in branded and specialty segments. The deal is subject to customary closing conditions and regulatory approvals.
